HK1247926A1 - 四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物 - Google Patents

四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物

Info

Publication number
HK1247926A1
HK1247926A1 HK18107440.1A HK18107440A HK1247926A1 HK 1247926 A1 HK1247926 A1 HK 1247926A1 HK 18107440 A HK18107440 A HK 18107440A HK 1247926 A1 HK1247926 A1 HK 1247926A1
Authority
HK
Hong Kong
Prior art keywords
forms
hydro
tetra
diphenyl
dimethyl
Prior art date
Application number
HK18107440.1A
Other languages
English (en)
Inventor
P‧約克
L‧A‧倫納德
D‧M‧萊杰
L‧S‧丹特里
Original Assignee
阿納韋克斯生命科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿納韋克斯生命科學公司 filed Critical 阿納韋克斯生命科學公司
Publication of HK1247926A1 publication Critical patent/HK1247926A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
HK18107440.1A 2015-07-22 2018-06-07 四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物 HK1247926A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195486P 2015-07-22 2015-07-22
PCT/IB2016/001181 WO2017013498A2 (en) 2015-07-22 2016-07-19 Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1247926A1 true HK1247926A1 (zh) 2018-10-05

Family

ID=57833871

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107440.1A HK1247926A1 (zh) 2015-07-22 2018-06-07 四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物

Country Status (7)

Country Link
US (4) US10413519B2 (zh)
EP (1) EP3325456A4 (zh)
JP (3) JP7304043B2 (zh)
CN (1) CN108026059A (zh)
CA (1) CA2986349A1 (zh)
HK (1) HK1247926A1 (zh)
WO (1) WO2017013498A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
EP3638225A1 (en) * 2017-06-14 2020-04-22 Anavex Life Sciences Corp. Anavex2-73 for the treatment of alzheimer's disease
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
AU2019269739A1 (en) 2018-05-18 2020-12-10 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
WO2023208133A1 (zh) * 2022-04-29 2023-11-02 苏州科睿思制药有限公司 布拉美森盐酸盐的晶型及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
GR1002616B (el) 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GR1006794B (el) * 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
GB201005623D0 (en) 2010-04-01 2010-05-19 Vantia Ltd New polymorph
GR1007686B (el) 2011-07-08 2012-09-12 Αλεξανδρος Δημητριου Βαμβακιδης Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
GR1008233B (el) 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
EP3324956A4 (en) 2015-07-22 2019-02-20 Anavex Life Sciences Corp. ENANTIOMERS OF TETRAHYDRO-N, N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE (ANAVEX2-73) AND USE THEREOF IN THE TREATMENT OF MORBUS ALZHEIMER AND OTHER FAILURES MODULATED BY THE SIGMA-1 RECEPTOR
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
CN108026059A (zh) 2018-05-11
CA2986349A1 (en) 2017-01-26
US20180169060A1 (en) 2018-06-21
WO2017013498A2 (en) 2017-01-26
WO2017013498A3 (en) 2017-03-02
JP2018524307A (ja) 2018-08-30
JP2021073300A (ja) 2021-05-13
EP3325456A4 (en) 2019-01-23
US11661405B2 (en) 2023-05-30
JP7304043B2 (ja) 2023-07-06
US10413519B2 (en) 2019-09-17
EP3325456A2 (en) 2018-05-30
US20210220321A1 (en) 2021-07-22
US10966952B2 (en) 2021-04-06
US20190350892A1 (en) 2019-11-21
JP2023083528A (ja) 2023-06-15
US20230278973A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
HK1247926A1 (zh) 四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物
ZA201601656B (en) Inhalable pharmaceutical composition
HK1245794A1 (zh) 咪唑並噁嗪晶體、含有所述晶體的藥物組合物和製備所述晶體的方法
HK1246641A1 (zh) 緩釋性醫藥組合物
IL304109A (en) Pharmaceutical preparations containing spinamide
HK1217303A1 (zh) 種治療白血病的藥物組合物及其製備方法
SI2774606T1 (sl) Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
HK1214767A1 (zh) 片劑形式的藥物組合物及其製造方法
HK1245094A1 (zh) 一種治療抑鬱症的藥物組合物及其製備方法
ZA201908090B (en) Pharmaceutical composition and method for preparing same
PL3250188T3 (pl) Kompozycja farmaceutyczna zawierająca Aprepitant oraz sposób jej wytwarzania
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
HK1246146A1 (zh) 用於治療真菌病的藥物組合物
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
GB201718483D0 (en) Pharmaceutical composition for treatment of meopausal syndrome and preparation method thereof
PL3290023T3 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca rywastygminę
EP3069723A4 (en) Naringin and levocetirizine hydrochloride pharmaceutical composition and preparation thereof
IL266938A (en) Pharmaceutical preparation and method for its manufacture
ZA201504398B (en) Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof
PL3558261T3 (pl) Kompozycje farmaceutyczne zawierające safinamid